Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis

Sergio D Rosenzweig, MD
Steven M Holland, MD
Section Editor
E Richard Stiehm, MD
Deputy Editor
Elizabeth TePas, MD, MS


Chronic granulomatous disease (CGD) is a genetically heterogeneous condition characterized by recurrent, life-threatening bacterial and fungal infections and granuloma formation. CGD is caused by defects in the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which constitutes the phagocyte oxidase (phox). These genetic defects result in the inability of phagocytes (neutrophils, monocytes, and macrophages) to destroy certain microbes. The diagnosis is made by neutrophil function testing, and then the exact defect is determined by genotyping.

Infections are generally caused by catalase-positive micro-organisms (most bacterial and all fungal pathogens are catalase positive). The frequent sites of infection are lung, skin, lymph nodes, and liver. The formation of granulomata is especially problematic in the gastrointestinal and genitourinary tracts. Other inflammatory manifestations are seen as well.

This topic will review the pathogenesis, clinical manifestations, and diagnosis of CGD. The treatment and prognosis of CGD, as well as an overview of primary disorders of phagocyte function, are discussed separately. (See "Chronic granulomatous disease: Treatment and prognosis" and "Primary disorders of phagocytic function: An overview".)


The frequency of chronic granulomatous disease (CGD) in the United States is approximately 1:200,000 live births [1]. The disease primarily affects males as most mutations are X linked. Rates are almost identical across ethnic and racial groups, with approximately one-third of the X-linked mutations occurring de novo. However, in cultures in which consanguineous marriage is common, the autosomal recessive forms of CGD are more common than X-linked forms, and overall incidence rates may be higher [2].

CGD may present at any time from infancy to late adulthood, but the majority of patients are diagnosed as toddlers and children before the age of five years. In several series, the median age at diagnosis was 2.5 to 3 years of age [3-6]. A growing number of patients are diagnosed in later childhood or adulthood. This is due in part to recognition of milder cases of autosomal recessive CGD, as well as delayed diagnosis in some patients. Diagnosis may be delayed because of potent antimicrobials that inadvertently treat many CGD-associated infections, postponing diagnosis until more severe infections indicate CGD as the underlying cause. X-linked CGD tends to have an earlier onset and be more severe than p47phox deficiency [1].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Dec 7, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155.
  2. Suliaman F, Amra N, Sheikh S, et al. Epidemiology of chronic granulomatous disease of childhood in Eastern Province, Saudi Arabia. Pediatr Asthma Allergy Immunol 2009; 22:21.
  3. Jones LB, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008; 152:211.
  4. Kobayashi S, Murayama S, Takanashi S, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr 2008; 167:1389.
  5. Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol 2008; 126:155.
  6. Soler-Palacín P, Margareto C, Llobet P, et al. Chronic granulomatous disease in pediatric patients: 25 years of experience. Allergol Immunopathol (Madr) 2007; 35:83.
  7. Segal BH, Leto TL, Gallin JI, et al. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000; 79:170.
  8. Curnutte JT, Babior BM. Chronic granulomatous disease. Adv Hum Genet 1987; 16:229.
  9. Segal AW. The electron transport chain of the microbicidal oxidase of phagocytic cells and its involvement in the molecular pathology of chronic granulomatous disease. J Clin Invest 1989; 1057:281.
  10. Dinauer MC. The respiratory burst oxidase and the molecular genetics of chronic granulomatous disease. Crit Rev Clin Lab Sci 1993; 30:329.
  11. Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010; 33:657.
  12. Flannagan RS, Jaumouillé V, Grinstein S. The cell biology of phagocytosis. Annu Rev Pathol 2012; 7:61.
  13. Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002; 416:291.
  14. Hartl D, Lehmann N, Hoffmann F, et al. Dysregulation of innate immune receptors on neutrophils in chronic granulomatous disease. J Allergy Clin Immunol 2008; 121:375.
  15. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007; 5:577.
  16. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303:1532.
  17. Bianchi M, Niemiec MJ, Siler U, et al. Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J Allergy Clin Immunol 2011; 127:1243.
  18. Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009; 114:2619.
  19. Hakkim A, Hurwitz R, Bianchi M, et al. Protecting against Aspergillus infection in CGD Response. Blood 2009; 114:3498.
  20. Romani L, Fallarino F, De Luca A, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008; 451:211.
  21. De Ravin SS, Zarember KA, Long-Priel D, et al. Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease. Blood 2010; 116:1755.
  22. Brown KL, Bylund J, MacDonald KL, et al. ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease. Clin Immunol 2008; 129:90.
  23. van de Veerdonk FL, Smeekens SP, Joosten LA, et al. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A 2010; 107:3030.
  24. Meissner F, Seger RA, Moshous D, et al. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 2010; 116:1570.
  25. van Bruggen R, Köker MY, Jansen M, et al. Human NLRP3 inflammasome activation is Nox1-4 independent. Blood 2010; 115:5398.
  26. Fernandez-Boyanapalli RF, Frasch SC, McPhillips K, et al. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood 2009; 113:2047.
  27. Sanmun D, Witasp E, Jitkaew S, et al. Involvement of a functional NADPH oxidase in neutrophils and macrophages during programmed cell clearance: implications for chronic granulomatous disease. Am J Physiol Cell Physiol 2009; 297:C621.
  28. Fernandez-Boyanapalli RF, Falcone EL, Zerbe CS, et al. Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment. J Allergy Clin Immunol 2015; 136:1399.
  29. Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010; 45:246.
  30. Dekker J, de Boer M, Roos D. Gene-scan method for the recognition of carriers and patients with p47(phox)-deficient autosomal recessive chronic granulomatous disease. Exp Hematol 2001; 29:1319.
  31. Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis 2010; 44:291.
  32. Matute JD, Arias AA, Wright NA, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009; 114:3309.
  33. Kurkchubasche AG, Panepinto JA, Tracy TF Jr, et al. Clinical features of a human Rac2 mutation: a complex neutrophil dysfunction disease. J Pediatr 2001; 139:141.
  34. Accetta D, Syverson G, Bonacci B, et al. Human phagocyte defect caused by a Rac2 mutation detected by means of neonatal screening for T-cell lymphopenia. J Allergy Clin Immunol 2011; 127:535.
  35. Bustamante J, Arias AA, Vogt G, et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol 2011; 12:213.
  36. Esfandbod M, Kabootari M. Images in clinical medicine. Chronic granulomatous disease. N Engl J Med 2012; 367:753.
  37. Marciano BE, Spalding C, Fitzgerald A, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis 2015; 60:1176.
  38. Dorman SE, Guide SV, Conville PS, et al. Nocardia infection in chronic granulomatous disease. Clin Infect Dis 2002; 35:390.
  39. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998; 77:345.
  40. Galluzzo ML, Hernandez C, Davila MT, et al. Clinical and histopathological features and a unique spectrum of organisms significantly associated with chronic granulomatous disease osteomyelitis during childhood. Clin Infect Dis 2008; 46:745.
  41. Bortoletto P, Lyman K, Camacho A, et al. Chronic Granulomatous Disease: A Large, Single-center US Experience. Pediatr Infect Dis J 2015; 34:1110.
  42. Salvator H, Mahlaoui N, Catherinot E, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. Eur Respir J 2015; 45:1613.
  43. Ramanuja S, Wolf KM, Sadat MA, et al. Newly diagnosed chronic granulomatous disease in a 53-year-old woman with Crohn disease. Ann Allergy Asthma Immunol 2005; 95:204.
  44. O'Neil KM, Herman JH, Modlin JF, et al. Pseudomonas cepacia: an emerging pathogen in chronic granulomatous disease. J Pediatr 1986; 108:940.
  45. Greenberg DE, Goldberg JB, Stock F, et al. Recurrent Burkholderia infection in patients with chronic granulomatous disease: 11-year experience at a large referral center. Clin Infect Dis 2009; 48:1577.
  46. Friend JC, Hilligoss DM, Marquesen M, et al. Skin ulcers and disseminated abscesses are characteristic of Serratia marcescens infection in older patients with chronic granulomatous disease. J Allergy Clin Immunol 2009; 124:164.
  47. Bustamante J, Aksu G, Vogt G, et al. BCG-osis and tuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol 2007; 120:32.
  48. Lau YL, Chan GC, Ha SY, et al. The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin Infect Dis 1998; 26:226.
  49. Lee PP, Chan KW, Jiang L, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J 2008; 27:224.
  50. Rosenzweig S, personal communication, 2010.
  51. Greenberg DE, Ding L, Zelazny AM, et al. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog 2006; 2:e28.
  52. Greenberg DE, Shoffner AR, Zelazny AM, et al. Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease. Emerg Infect Dis 2010; 16:1341.
  53. López FC, de Luna FF, Delgado MC, et al. Granulibacter bethesdensis isolated in a child patient with chronic granulomatous disease. J Infect 2008; 57:275.
  54. Sirinavin S, Techasaensiri C, Pakakasama S, et al. Hemophagocytic syndrome and Burkholderia cepacia splenic microabscesses in a child with chronic granulomatous disease. Pediatr Infect Dis J 2004; 23:882.
  55. Hisano M, Sugawara K, Tatsuzawa O, et al. Bacteria-associated haemophagocytic syndrome and septic pulmonary embolism caused by Burkholderia cepacia complex in a woman with chronic granulomatous disease. J Med Microbiol 2007; 56:702.
  56. Lacy DE, Spencer DA, Goldstein A, et al. Chronic granulomatous disease presenting in childhood with Pseudomonas cepacia septicaemia. J Infect 1993; 27:301.
  57. Macher AM, Casale TB, Fauci AS. Chronic granulomatous disease of childhood and Chromobacterium violaceum infections in the southeastern United States. Ann Intern Med 1982; 97:51.
  58. Mailman TL, Schmidt MH. Francisella philomiragia adenitis and pulmonary nodules in a child with chronic granulomatous disease. Can J Infect Dis Med Microbiol 2005; 16:245.
  59. Reichenbach J, Lopatin U, Mahlaoui N, et al. Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis 2009; 49:1703.
  60. Falcone EL, Holland SM. Streptococcal infections in patients with chronic granulomatous disease: case report and review of the literature. J Clin Immunol 2013; 33:310.
  61. Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49:102.
  62. Vinh DC, Shea YR, Jones PA, et al. Chronic invasive aspergillosis caused by Aspergillus viridinutans. Emerg Infect Dis 2009; 15:1292.
  63. De Ravin SS, Challipalli M, Anderson V, et al. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis 2011; 52:e136.
  64. Machouart M, Garcia-Hermoso D, Rivier A, et al. Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. J Clin Microbiol 2011; 49:1681.
  65. Sponseller PD, Malech HL, McCarthy EF Jr, et al. Skeletal involvement in children who have chronic granulomatous disease. J Bone Joint Surg Am 1991; 73:37.
  66. Henriet SS, Verweij PE, Warris A. Aspergillus nidulans and chronic granulomatous disease: a unique host-pathogen interaction. J Infect Dis 2012; 206:1128.
  67. Santos PE, Piontelli E, Shea YR, et al. Penicillium piceum infection: diagnosis and successful treatment in chronic granulomatous disease. Med Mycol 2006; 44:749.
  68. Vinh DC, Freeman AF, Shea YR, et al. Mucormycosis in chronic granulomatous disease: association with iatrogenic immunosuppression. J Allergy Clin Immunol 2009; 123:1411.
  69. Lugo Reyes SO, Suarez F, Herbigneaux RM, et al. Hodgkin lymphoma in 2 children with chronic granulomatous disease. J Allergy Clin Immunol 2011; 127:543.
  70. Towbin AJ, Chaves I. Chronic granulomatous disease. Pediatr Radiol 2010; 40:657.
  71. Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). J Clin Immunol 2008; 28 Suppl 1:S67.
  72. Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004; 114:462.
  73. Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010; 51:1429.
  74. Feld JJ, Hussain N, Wright EC, et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology 2008; 134:1917.
  75. Walther MM, Malech H, Berman A, et al. The urological manifestations of chronic granulomatous disease. J Urol 1992; 147:1314.
  76. Goldblatt D, Butcher J, Thrasher AJ, Russell-Eggitt I. Chorioretinal lesions in patients and carriers of chronic granulomatous disease. J Pediatr 1999; 134:780.
  77. Wang Y, Marciano BE, Shen D, et al. Molecular identification of bacterial DNA in the chorioretinal scars of chronic granulomatous disease. J Clin Immunol 2013; 33:917.
  78. Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 2007; 45:673.
  79. Cohen MS, Leong PA, Simpson DM. Phagocytic cells in periodontal defense. Periodontal status of patients with chronic granulomatous disease of childhood. J Periodontol 1985; 56:611.
  80. Scully C. Orofacial manifestations of chronic granulomatous disease of childhood. Oral Surg Oral Med Oral Pathol 1981; 51:148.
  81. Buduneli N, Baylas H, Aksu G, Kütükçüler N. Prepubertal periodontitis associated with chronic granulomatous disease. J Clin Periodontol 2001; 28:589.
  82. Oveisi M, Barzilay O, Hanafi AA. Periodontal Disease in Immunodeficient Patients: Clinical Guidelines for Diagnosis and Management. International Dental Journal of Student’s Research 2015; 3:95.
  83. Manzi S, Urbach AH, McCune AB, et al. Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. Arthritis Rheum 1991; 34:101.
  84. Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 2007; 148:79.
  85. De Ravin SS, Naumann N, Cowen EW, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol 2008; 122:1097.
  86. Buescher ES, Gallin JI. Stature and weight in chronic granulomatous disease. J Pediatr 1984; 104:911.
  87. Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009; 145:73.
  88. Marsh WL, Oyen R, Nichols ME, Allen FH Jr. Chronic granulomatous disease and the Kell blood groups. Br J Haematol 1975; 29:247.
  89. Frey D, Mächler M, Seger R, et al. Gene deletion in a patient with chronic granulomatous disease and McLeod syndrome: fine mapping of the Xk gene locus. Blood 1988; 71:252.
  90. Repine JE, Clawson CC, White JG, Holmes B. Spectrum of function of neutrophils from carriers of sex-linked chronic granulomatous disease. J Pediatr 1975; 87:901.
  91. Anderson-Cohen M, Holland SM, Kuhns DB, et al. Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation. Clin Immunol 2003; 109:308.
  92. Wolach B, Scharf Y, Gavrieli R, et al. Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB. Blood 2005; 105:61.
  93. Roesler J. Carriers of X-linked chronic granulomatous disease at risk. Clin Immunol 2009; 130:233; author reply 234.
  94. Lewis EM, Singla M, Sergeant S, et al. X-linked chronic granulomatous disease secondary to skewed X chromosome inactivation in a female with a novel CYBB mutation and late presentation. Clin Immunol 2008; 129:372.
  95. Rösen-Wolff A, Soldan W, Heyne K, et al. Increased susceptibility of a carrier of X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection associated with age-related skewing of lyonization. Ann Hematol 2001; 80:113.
  96. Brandrup F, Koch C, Petri M, et al. Discoid lupus erythematosus-like lesions and stomatitis in female carriers of X-linked chronic granulomatous disease. Br J Dermatol 1981; 104:495.
  97. Kragballe K, Borregaard N, Brandrup F, et al. Relation of monocyte and neutrophil oxidative metabolism to skin and oral lesions in carriers of chronic granulomatous disease. Clin Exp Immunol 1981; 43:390.
  98. Vowells SJ, Sekhsaria S, Malech HL, et al. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods 1995; 178:89.
  99. Vowells SJ, Fleisher TA, Sekhsaria S, et al. Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease. J Pediatr 1996; 128:104.
  100. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363:2600.
  101. Mauch L, Lun A, O'Gorman MR, et al. Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem 2007; 53:890.
  102. Ferguson PJ, Lokuta MA, El-Shanti HI, et al. Neutrophil dysfunction in a family with a SAPHO syndrome-like phenotype. Arthritis Rheum 2008; 58:3264.
  103. Roos D, van Zwieten R, Wijnen JT, et al. Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 1999; 94:2955.
  104. Whitin JC, Cohen HJ. Disorders of respiratory burst termination. Hematol Oncol Clin North Am 1988; 2:289.
  105. Ristoff E, Mayatepek E, Larsson A. Long-term clinical outcome in patients with glutathione synthetase deficiency. J Pediatr 2001; 139:79.
  106. Banerjee R, Anguita J, Roos D, Fikrig E. Cutting edge: infection by the agent of human granulocytic ehrlichiosis prevents the respiratory burst by down-regulating gp91phox. J Immunol 2000; 164:3946.